adctherapeutics.com (ADCT): Forward P/S Multiple

Corporate emblem and logo of ADC Therapeutics S.A. (ADCT)

The development of blood cancer therapies is not subject to market cycles, and the growth of ADC Therapeutics (ADCT) shares depends on the success of new drugs. Zynlonta sales are creating current momentum while combination tests are being prepared. Patent protection and strict FDA oversight create barriers for competitors. The forward price-to-sales valuation trend shows that the parameter value is 2.00, illustrating market expectations for the business valuation.

ADC Therapeutics S.A. - ADCT Forward Price-to-Revenue Multiple (period 07/04/2022 - 11/15/2026)

Analytical breakdowns for ADC Therapeutics (ADCT)

- current price and projected stock value:
Stock Price ADC Therapeutics S.A.|ADCT - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Capitalization ADC Therapeutics Corp|ADCT - Business Value
- issuer book value statistics:
Book Value per Share ADC Therapeutics|ADCT - Company Net Assets|Market Cap to Net Assets Ratio adctherapeutics.com|ADCT - Aggregate Asset Value
- company total debt and liquidity indicators:
Total Debt to Equity Ratio ADC Therapeutics|ADCT - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital ADC Therapeutics SA|ADCT - Aggregate Debt Obligations|Debts to Book Capitalization ADC Pharma|ADCT - Long-Term Debt|Company Short-Term Debt ADC Therapeutics|Quick Ratio adctherapeutics.com
- financial results and valuation multiples details:
ADCT - Net Profit|Expected Profit ADC Therapeutics|ADCT - Market Cap to Net Income|Forward P/E Multiple ADC Therapeutics S.A.|ADCT - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio ADC Therapeutics|ADCT - Operating profit EBITDA|Net earnings per share for the last 12 months ADC Therapeutics|ADCT - Earnings per share for the last four quarters|Quarterly EPS earnings growth adctherapeutics.com|ADCT - Expected net earnings per share growth this year|Earnings growth forecast for next year ADC Therapeutics
- sales and revenue data:
ADCT - Company Sales|Company Projected Revenue ADC Pharma|ADCT - Price-to-Revenue Coefficient|Forward P/S Multiple ADC Therapeutics
Summary company analysis:adctherapeutics.com ADCT
Manufactured products of ADC Pharma

Investors are assessing the resilience of ADC Therapeutics (ADCT) through the ratio of market capitalization to projected revenue, which determines the extent of the premium paid for future sales. By analyzing the forward P/S dynamics of ADC Therapeutics, one can see how the market prices in the value of an oncology business whose operating losses and high R&D expenses render traditional profit metrics inapplicable for fundamental valuation.

Competitor analysis

TG Therapeutics - Forward Price-to-Revenue Multiple|Forward P/S Multiple Arcellx Therapeutics ACLX|discmedicine.com - Forward P/S Multiple|Market Cap to Future Revenue Ratio syndax.com|Kura Oncology (KURA) - Price-to-Projected Revenue Ratio|Projected Price to Revenue Foghorn Therapeutics, Inc. FHTX|VOR (Vor Bio) - Forward P/S Multiple|NKTX: Forward Price to Sales|Forward Price-to-Revenue Multiple COEP (Coeptis Therapeutics)|Actinium Pharmaceuticals - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Estrella Immunopharma, Inc. ESLA|CASI (CASI Pharmaceuticals, Inc) - Future Price to Revenue|MRKR: Forward Price-to-Revenue Multiple|INAB - Forward P/S Multiple|ERNA (eternatx.com) - Forward Price-to-Revenue Multiple|GT Biopharma, Inc. - Forward Price to Sales|APTO (Aptose Biosciences) - Forward P/S Multiple|BPTH: Forward Price to Sales|Forward P/S Multiple MEIP|VINC (Vincerx Pharma) - Forward Price to Sales